Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
Xinxin Zhu, Jinghe Lang
Oncotarget (2017) Vol. 8, Iss. 57, pp. 97671-97682
Open Access | Times Cited: 279

Showing 1-25 of 279 citing articles:

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Yilun Wu, Weiyu Chen, Zhi Ping Xu, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 358
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang Qing, Yun Chen, Xiaojuan Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 286
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
Bo Gong, Kazuma Kiyotani, Seiji Sakata, et al.
The Journal of Experimental Medicine (2019) Vol. 216, Iss. 4, pp. 982-1000
Open Access | Times Cited: 214
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
Yi‐Ting Wang, Huanbin Wang, Han Yao, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 195
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
Kristina Buder‐Bakhaya, Jessica C. Hassel
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 192
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Sanjeevani Arora, R. A. Velichinskii, Randy W. Lesh, et al.
Advances in Therapy (2019) Vol. 36, Iss. 10, pp. 2638-2678
Open Access | Times Cited: 173
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Remy Thomas, Ghaneya Al‐Khadairi, Julie Decock
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 132
The Role of the Immune System in the Development of Endometriosis
Monika Abramiuk, Ewelina Grywalska, Paulina Małkowska, et al.
Cells (2022) Vol. 11, Iss. 13, pp. 2028-2028
Open Access | Times Cited: 114
The role of biomarkers in personalized immunotherapy
K. Nathan Sankar, Jing Christine Ye, Zihai Li, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 71
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
Yo-Ting Tsai, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 17
Targeting PVR (CD155) and its receptors in anti-tumor therapy
Paola Kučan Brlić, T. Rovis, Guy Cinamon, et al.
Cellular and Molecular Immunology (2018) Vol. 16, Iss. 1, pp. 40-52
Open Access | Times Cited: 144
Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
Muhammad Khan, Zhihong Zhao, Sumbal Arooj, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 134
The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
Linda Quatrini, Francesca Romana Mariotti, Enrico Munari, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3285-3285
Open Access | Times Cited: 122
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
Kathleen M. Mahoney, Sachet A. Shukla, Nikolaos Patsoukis, et al.
Cancer Immunology Immunotherapy (2018) Vol. 68, Iss. 3, pp. 421-432
Open Access | Times Cited: 117
ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma
Luqing Tong, Jiabo Li, Qiuying Li, et al.
Theranostics (2020) Vol. 10, Iss. 13, pp. 5943-5956
Open Access | Times Cited: 113
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study
Seok Jin Kim, Jing Quan Lim, Yurike Laurensia, et al.
Blood (2020) Vol. 136, Iss. 24, pp. 2754-2763
Open Access | Times Cited: 105
Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression
Yanxia Guo, Alice M. Walsh, Mary Canavan, et al.
PLoS ONE (2018) Vol. 13, Iss. 2, pp. e0192704-e0192704
Open Access | Times Cited: 99
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
Manuela Tiako Meyo, Anne Jouinot, Étienne Giroux-Leprieur, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 473-473
Open Access | Times Cited: 98
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
Christian Bailly, Xavier Thuru, Bruno Quesnel
Cancers (2021) Vol. 13, Iss. 12, pp. 3034-3034
Open Access | Times Cited: 97
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma
Selma Ugurel, Dirk Schadendorf, Kai Horny, et al.
Annals of Oncology (2020) Vol. 31, Iss. 1, pp. 144-152
Open Access | Times Cited: 96
Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
So Yeon Oh, Soyeon Kim, Bhumsuk Keam, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 93
Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients
Florence de Fraipont, Sylvie Gazzéri, William C. Cho, et al.
Frontiers in Genetics (2019) Vol. 10
Open Access | Times Cited: 91
Ginseng-derived nanoparticles potentiate immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment
Xuan Han, Wei Qin, Yan Lv, et al.
Molecular Therapy (2021) Vol. 30, Iss. 1, pp. 327-340
Open Access | Times Cited: 89
PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression
Francesca Romana Mariotti, Stefania Petrini, Tiziano Ingegnere, et al.
OncoImmunology (2018) Vol. 8, Iss. 3, pp. 1557030-1557030
Open Access | Times Cited: 85
PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury
Evangelos Triantafyllou, Cathrin Gudd, Marie‐Anne Mawhin, et al.
Journal of Clinical Investigation (2020) Vol. 131, Iss. 4
Open Access | Times Cited: 82
Page 1 - Next Page

Scroll to top